Allan Hackshaw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Allan Hackshaw has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
E A Paul
11Barts & The London School of Medicine & Dentistry, Wolfson Institute of Environmental & Preventive Medicine, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
1 shared publicationNicholas Wald
Wolfson Institute of Environmental and Preventive Medicine, Bortholorews and the London School of Medicine and Dentistry, Queen Mary's University of London, Charterhouse Square, London ECIM 6BQ
1 shared publication
Latest Publications
- Open Access
- 1 April 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (7) , 1047-1053
Breast self-examination and death from breast cancer: a meta-analysis
Breast self-examination (BSE) is widely recommended for breast cancer prevention. Following recent controversy over the efficacy of mammography, it may be seen as an alternative. We present a meta-analysis of the effect of regular BSE on breast cancer mortality. From a search of the medical literature, 20 observational studies and three clinical trials were identified that reported on breast cancer death rates or rates of advanced breast cancer (a marker of death) according to BSE practice. A lower risk of mortality or advanced breast cancer was only found in studies of women with breast cancer who reported practising BSE before diagnosis (mortality: pooled relative risk 0.64, 95% CI 0.56–0.73; advanced cancer, pooled relative risk 0.60, 95% CI 0.46–0.80). The results are probably due to bias and confounding. There was no difference in death rate in studies on women who detected their cancer during an examination (pooled relative risk 0.90, 95% CI 0.72–1.12). None of the trials of BSE training (in which most women reported practising it regularly) showed lower mortality in the BSE group (pooled relative risk 1.01, 95% CI 0.92–1.12). They did show that BSE is associated with considerably more women seeking medical advice and having biopsies. Regular BSE is not an effective method of reducing breast cancer mortality.
- 1 April 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (7) , 1047-1053
Open AccessBreast self-examination and death from breast cancer: a meta-analysis
Breast self-examination (BSE) is widely recommended for breast cancer prevention. Following recent controversy over the efficacy of mammography, it may be seen as an alternative. We present a meta-analysis of the effect of regular BSE on breast cancer mortality. From a search of the medical literature, 20 observational studies and three clinical trials were identified that reported on breast cancer death rates or rates of advanced breast cancer (a marker of death) according to BSE practice. A lower risk of mortality or advanced breast cancer was only found in studies of women with breast cancer who reported practising BSE before diagnosis (mortality: pooled relative risk 0.64, 95% CI 0.56–0.73; advanced cancer, pooled relative risk 0.60, 95% CI 0.46–0.80). The results are probably due to bias and confounding. There was no difference in death rate in studies on women who detected their cancer during an examination (pooled relative risk 0.90, 95% CI 0.72–1.12). None of the trials of BSE training (in which most women reported practising it regularly) showed lower mortality in the BSE group (pooled relative risk 1.01, 95% CI 0.92–1.12). They did show that BSE is associated with considerably more women seeking medical advice and having biopsies. Regular BSE is not an effective method of reducing breast cancer mortality.
- 31 October 2002
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (11) , 1051-1053
Estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening
- 31 October 2002
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (11) , 1051-1053
Estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening